[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Ltl Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fexofenadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Ltl Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Ltl Pharma"},{"orgOrder":0,"company":"John Muir Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pseudoephedrine","moa":"Norepinephrine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"John Muir Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Pill","sponsorNew":"John Muir Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"John Muir Health \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for ( )-Pseudoephedrine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Allegra-D (fexofenadine) is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies.

                          Product Name : Allegra-D

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 22, 2022

                          Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine

                          Therapeutic Area : Immunology

                          Study Phase : Approved FDF

                          Sponsor : Ltl Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).

                          Product Name : Diregura

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 04, 2020

                          Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Ltl Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Sanofi Company Banner

                          03

                          John Muir Health

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          John Muir Health

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Pseudoephedrine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Barotrauma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 25, 2023

                          Lead Product(s) : Pseudoephedrine

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank